I would just add that we are working very aggressively with the list of drugs that are on special access, especially for the rare diseases, to bring those into some kind of authorized state.
In working with the companies, it's a matter of would it take to get them to file for approval of a product in Canada. If they have filed to another jurisdiction and they have the medication approved there, we will use the assessment reports of those regulators, the decision that regulator made, to help us get those products off SAP and into a marketed state, so that the patients, families and physicians don't have to go through the special access program.